Literature DB >> 16965388

High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005.

Kristina Karrman1, Erik Forestier, Mette K Andersen, Kirsi Autio, Georg Borgström, Sverre Heim, Kristina Heinonen, Randi Hovland, Gitte Kerndrup, Bertil Johansson.   

Abstract

Trisomy 21 is common in ETV6/RUNX1-positive acute lymphoblastic leukaemia (ALL); both these aberrations are associated with a favourable outcome. The prognostic impact of +21 as a sole cytogenetic change could be due to a cryptic t(12;21)(p13;q22). The occurrence of ETV6/RUNX1 was determined in 66 childhood ALLs with an acquired +21 and a chromosome number <51. ETV6/RUNX1 was found in 45% of cases and in the majority (10/18; 56%) of ALLs with sole +21. Event-free survival did not differ between the t(12;21)-positive and -negative cases. Thus, the prognostic impact of +21 is not attributable to cryptic ETV6/RUNX1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965388     DOI: 10.1111/j.1365-2141.2006.06286.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Emerging technologies in paediatric leukaemia.

Authors:  Amanda Dixon-McIver
Journal:  Transl Pediatr       Date:  2015-04

2.  Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?

Authors:  Maj A Hultén; Jon Jonasson; Ann Nordgren; Erik Iwarsson
Journal:  Curr Genomics       Date:  2010-09       Impact factor: 2.236

3.  Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).

Authors:  Ayalew Tefferi; Dame Idossa; Terra L Lasho; Mythri Mudireddy; Christy Finke; Sahrish Shah; Maura Nicolosi; Mrinal M Patnaik; Animesh Pardanani; Naseema Gangat; Curt A Hanson; Rhett P Ketterling
Journal:  Blood Cancer J       Date:  2017-12-18       Impact factor: 11.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.